San Diego-based MabVax Therapeutics Inc., a privately held clinical stage biotechnology company, has announced the closing of the first tranche in its Series B financing.
MabVax Therapeutics focuses on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer.
Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million.
The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.
The financing provides MabVax access to Numoda's advanced and patented clinical trial information technologies and management systems. These technologies will enable MabVax to move through the clinical trial process efficiently while providing visibility for reporting early assessments and timely trial results.